

**AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

Claims 1-21. (Canceled)

22. (Previously Presented) Immunogenic compositions, characterized in that they are created from preparations obtained by:

incubation of first means expressing the target receptor(s) of an infectious pathogenic agent, causing infections in a mammal by bonding and then fusion with target cells, with second means expressing at least the regions of the pathogenic agent recognizing the said targets under conditions enabling interaction of the first and second means so as to form a complex,

this incubation step being done with different intervals in order to produce complexes corresponding to different fusion stages, and

putting the complexes formed into contact with a binding agent for different intervals, in order to bind complexes with different exposures and conformations of epitopes against which antibodies are to be formed,

the said first and second means being tolerated by mammals.

23. (Currently Amended) Compositions according to claim 22, characterized in that the first means are autologous mammal cells, ~~and particularly healthy human cells taken from a patient to be vaccinated.~~

24. (Currently Amended) Compositions according to claim 22, characterized in that the first means are vectors comprising genes expressing the target receptor(s) ~~at their surface~~.

25. (Previously Presented) Compositions according to claim 22, characterized in that the first means are liposomes bringing the said receptor(s) to their surface.

26. (Previously Presented) Compositions according to claim 22, characterized in that the second means are previously transformed cells with a vector carrying at least one bonding region to at least one receptor.

27. (Previously Presented) Compositions according to claim 22 characterized in that the second means are made from viral vectors carrying at least one bonding region to a target receptor.

28. (Previously Presented) Compositions according to claim 22, characterized in that the second means used are infected cells that produce pathogenic agents or are composed of infectious pathogenic agents.

29. (Previously Presented) Compositions according to claim 22, characterized in that the said pathogenic agents are viruses.

30. (Previously Presented) Compositions according to claim 29, characterized in that the pathogenic agent is HIV.

31. (Previously Presented) Compositions according to claim 22, characterized in that the said preparations are obtained by incubation of first means expressing the CD4 receptor and/or HIV co-receptors with second means expressing at least the preserved regions in gp120 or gp160 envelope proteins.

32. (Previously Presented) Compositions according to claim 31, characterized by the fact that the first means used are composed of autologous cells of mammals stimulated so as to express the CD4 receptor and/or HIV co-receptors, in a sufficient quantity for the required interaction.

33. (Currently Amended) Compositions according to claim 31, characterized in that the first means are viral vectors comprising genes expressing CD4 and/or HIV co-receptors ~~such as baculovirus, the Semliki forest virus or yeast such as Saccharomyces cerevisiae, at their surface.~~

34. (Previously Presented) Compositions according to claim 31, characterized in that the first means are liposomes expressing the CD4 receptor and/or HIV co-receptors at their surface, the said expression being made by viral vectors.

35. (Currently Amended) Compositions according to claim 31, characterized in that the second means are composed of previously transformed cells with a viral vector comprising at least ~~the preserved regions~~ [[in]] of HIV-1 gp120 or HIV-1 gp160 envelope proteins, or are composed of such viral vectors.

36. (Previously Presented) Compositions according to claim 31, characterized in that the second means are infected cells producing HIV or are composed of the HIV virus itself.

37. (Currently Amended) Compositions according to claim 31, characterized in that the second means are composed of HIV-1 gp120 or HIV-1 gp160 envelope proteins in natural or recombining form, ~~or of at least the preserved regions of these proteins.~~

38. (Currently Amended) Compositions according to claim 31, characterized in that one of the co-receptors of HIV is replaced by a monoclonal antibody directed to a region of gp120 which binds to HIV-1 co-receptors.

Claim 39. (Cancelled)

40. (Previously Presented) Compositions according to claim 22 characterized in that the preparations are fixed with aldidrithiol-2 after incubation.

41. (Currently Amended) An isolated [[serums]]serum or antibody formed against a composition according to claim 22.

42. (Currently Amended) Compositions ~~Vaccinal compositions against an infectious pathology intended for administration to a mammal, characterized in that they contain an effective quantity of an immunogenic composition according to claim 22,~~ further comprising [[with]] an inert vehicle acceptable for administration to a mammal, and optionally with an additive.

43. (Previously Presented) Compositions according to claim 24, characterized in that the vectors are viral vectors.

44. (Currently Amended) Compositions according to claim ~~[[29]]~~28, characterized in that the ~~viruses~~pathogenic agents are selected from the group consisting of a retrovirus, a bacteria, a mycobacteria, and a parasite.

45. (Currently Amended) Compositions according to claim ~~[[24]]~~28, characterized in that the ~~viruses~~pathogenic agents are selected from the group consisting of a *Plasmodium sp*, a *Leishmania sp*, *Trypanosoma cruzi* and *Trypanosoma brucei*.

46. (new) A composition according to claim 23, characterized in that the first means are healthy human cells taken from a patient to be vaccinated.

47. (new) Compositions according to claim 33, wherein the vectors are a *baculovirus* or the Semliki forest virus.

48. (new) Compositions according to claim 31, characterized in that the first means are yeast expressing CD4 and/or HIV co-receptors at their surface.

49. (new) Compositions according to claim 48 wherein said yeast are a *Saccharomyces cerevi*.